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Purpose: The aim of this study was to show the efficiency of preoperative botulinum toxin A 
(Botox A) in patients with benign essential blepharospasm who were to undergo ocular surgery 
with local anesthesia.
Materials and methods: Twenty-eight benign essential blepharospasm patients who were 
administered unilateral Botox A prior to ocular surgery between January 2004 and May 2011 
were included in this study. Eleven cases had pterygiums, ten had cataracts, and four had 
glaucomas, while the remaining three had aphakia. All cases’ severity of spasm (stage 0–4) 
and eyelid closing forces (stage 1–4) were evaluated according to the Jankovic scale prior to 
the injection, at 3 days, 14 days, 1 month, and 3 months after Botox A injection.
Results: Of the patients enrolled in the study, 16 were female and 12 were male, with an average 
age of 55.52 ± 1.53 years (52–65). Average onset of the Botox injection’s effect was 2.8 ± 0.9 
(2–5) days. Its effect lingered for about 11.5 ± 3.6 (8–22) weeks. The severity of spasm and 
eyelid closing forces of all the patients enrolled were compared prior to the injection at 3 and 
14 days and the first and third months after the injection. There were statistically significant 
differences between prior to the injection and 3 days (P = 0.001), 14 days (P , 0.001) and 
1 month after the injection (P , 0.001). There was no statistically significant difference between 
prior to the injection and 3 months after the injection (P = 0.513). Fourteen days following the 
injection, the surgeries were successfully performed.
Conclusion: Botox A administered prior to ocular surgery will control both blepharospasm and 
lower the risks that can be encountered before and during surgery, thus increasing the comfort 
of the patient and the surgeon.
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Introduction
Benign essential blepharospasm (BEB) is thought to be due to overexcitement of the 
neurons in the brain stem that results from the organic dysfunction of the basal ganglia, 
characterized by involuntary overcontraction of the orbicularis oculi.1–3 BEB typically 
has an onset in the sixth decade, and it is more common in women.4 The main symptoms 
of blepharospasm are grumbling facial expression, fluttering of eyelids, increase in 
the frequency of blinking, and chronic involuntary contractions that eventually affect 
both eyes. In cases with BEB, tonic essential spasm of the orbicularis oculi muscle can 
lead to total closure of both eyelids.5 As a result, activities such as reading, writing, 
and driving become hard to accomplish for patients, with blepharospasms having a 
negative effect on the quality of life.6
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Botulinum toxin type A (Botox A) enables neuromuscular 
blockade by preventing acetylcholine secretion from the 
presynaptic vesicles. Botox A is currently the gold-standard 
therapy of benign essential blepharospasm due to its effi-
ciency and safety.7,8
Ocular surgeries can be performed by using topical or local 
anesthetics. However, performing surgery in patients with tonic 
contraction of eyelids could be hard for both the surgeon and 
the patient. Additionally, preoperative anxiety of the patient, 
preoperative pain, and exposure to the light of the surgery 
microscope can cause an increase in the frequency of blinking 
and involuntary contractions. Surgery in a patient with per-
sistent involuntary contractions of the eyelids is an undesired 
condition. The aim of this study was to show the efficacy of 
Botox A in patients with benign essential blepharospasm who 
were to undergo ocular surgery under local anesthesia.
Materials and methods
Twenty-eight BEB patients who were administered with 
unilateral Botox A prior to ocular surgery between January 
2004 and May 2011 were included in this study. Eleven cases 
had pterygiums, ten had cataracts, and four had glaucomas, 
while the remaining three had aphakia. The diagnosis of BEB 
was ascertained by detailed ophthalmic and neurological 
examination. Patients who had systemic and neurological 
disorders and those who had previous Botox A injections 
were excluded from the study. Prior to the study, informed 
consent was obtained from the patients and local ethics com-
mittee approvals were completed according to Declaration of 
Helsinki. Severity of spasm (stage 0–4) and eyelid closing 
force (stage 1–4) were evaluated according to the Jankovic 
scale prior to the injection and at 3 days, 14 days, 1 month, 
and 3 months after Botox A injection9,10 (Table 1).
A Botox A vial (100 U) was diluted with 4 mL of saline 
that included no preservatives (0.9% NaCl). After the dilution, 
a solution that had 2.5 U of Botox A in each 0.1 mL was 
obtained. The areas that would be injected were marked after 
being cleansed by 10% povidone iodine solution. No other 
drugs were used, in order to prevent drug interaction. From the 
solution obtained, six injections were made with a 27-gauge 
insulin syringe. These injections were made to lateral and medial 
connections of the preseptal and orbital parts of the orbicularis 
oculi muscle, lateral and medial part of the pretarsal orbicu-
laris oculi muscle of the upper eyelid, lateral part of the lateral 
canthus, and pretarsal region of the lower eyelid (Figure 1). 
Compression was performed in the areas where injections 
were made. The severity of spasm and eyelid closing force 
for all the patients enrolled were measured according to the 
Jankovic scale prior to the injection and at 3 days, and 14 days, 
1 month, and 3 months after injection and compared.
Fourteen days after the injection, patients underwent ocular 
surgery under topical and/or sub-Tenon’s anesthesia by using eye 
speculum. Topical anesthesia was provided by 0.5% propara-
caine drops (Alcaine®; Alcon Laboratories, Inc, Fort Worth, TX), 
while sub-Tenon’s anesthesia was provided by a 2-cc injection 
of lidocaine HCl 20 mg/mL, epinephrine HCI 0.0125 mg/mL 
(Jetocain; Adeka, Samsun, Turkey). No sedatives were used for 
patients that may have interrupted the blepharospasm symptoms. 
The patients were evaluated for anterior segment and fundus, 
and intraocular pressure (IOP) was measured after operation.
Statistical analyses were performed using the Statisti-
cal Package for the Social Sciences (version 12.0; IBM, 
Armonk, NY). The Wilcoxon signed-rank test was used for 
the statistical analysis of severity of spasm and eyelid clos-
ing force prior to the injection and after injection. A P value 
of ,0.05 was accepted as statistically significant.
Results
Of the 28 patients enrolled in the study, 16 were female 
and 12 were male. The average age of the patients was 
Table 1 Severity of spasm and eyelid closing force scores
Grade Definition
Severity of spasm
0 No spasm
1 Mild spasm at stimulation only
2 Visible spasm without impairment of daily life
3 Visible spasm with impairment of daily life
4 Severe spasm with impairment of daily life
Eyelid closing force
1 Flaccid
2 Overcome with minimum resistance
3 Overcome with moderate resistance
4 Normal strength
Figure 1 Location of injections of Botox A.
Note: Arrows indicate orientation of the tip of needle.
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55.52 ± 1.53 years (52–65 years). Eye specula were used on 
all patients without trouble. There were not any complica-
tions due to involuntary eyelid contractions during surgery. 
Eleven eyes of eleven patients underwent pterygium excision 
and conjunctival autograft surgeries under subconjunctival 
anesthesia. Ten eyes of ten patients underwent phacoemul-
sification and intraocular lens implantation surgeries for 
cataract under topical anesthesia. Four patients underwent 
trabeculectomy under retrobulbar anesthesia. Three patients 
underwent secondary intraocular lens implantation under 
sub-Tenon’s anesthesia (Table 2).
The severity of spasm and eyelid closing forces of all the 
patients enrolled were compared prior to the injection and at 
3 days, 14 days and 1 and 3 months after the injection. There 
were statistically significant differences between prior to the 
injection and 3 days (P = 0.001), 14 days (P = 0.001) and 
1 month after the injection (P = 0.001). There was no statisti-
cally significant difference between prior to the injection and 
3 months after the injection (P = 0.513) (Table 3).
Corneal sutures of the patients who were given intraocular 
lenses with scleral fixation due to aphakia were removed in 
an average of 36.6 ± 6 days (30–42 days).
The average corrected preoperative visual acuity of the 
patients with cataract was 20/200 (20/640–20/80), while the 
postoperative value was 20/32 (20/80–20/25). Preoperative 
and postoperative values for patients who were given intraoc-
ular lenses with scleral fixation were 20/400 and 20/50, 
respectively. Preoperative and postoperative average IOP 
values for patients with glaucoma were 28.7 ± 3.6 mmHg 
and 18 ± 3.2 mmHg, respectively. Average onset of the 
Botox injection’s effect was 2.8 ± 0.9 (2–5) days. Its effect 
lingered for about 11.5 ± 3.6 (8–22) weeks. In follow-ups, it 
was determined that the effects of the injections were more 
evident on the 14th day and that the level of decrease in the 
blepharospasm degree and eyelid power was sufficient to let 
the eye speculum to be fastened.
None of the patients experienced diplopia, dry eye, keratitis, 
pain, lacrimation, blurry vision, or any systemic side effects. 
Eyelid echimosis was observed in two patients, while there was 
mild ptosis in one patient on the fourth postoperative day. The 
ptosis resolved on its own in approximately 2 months.
Discussion
Botox A is commonly used in the control of BEB, strabismus 
hemifacial spasm, cervical dystonia, spasticity, spastic entro-
pion, thyroid-associated upper eyelid contraction, and also it 
is used as an alternative to surgical tarsorrhaphy in cases with 
ocular surface disorders.7,8,11–19 The toxin has received Food 
and Drug Administration approval for treatment of blephar-
ospasm, strabismus, primary axillary hyperhidrosis, cervical 
dystonia and glabellar wrinkles, and brow furrows.20,21 Our 
indication for administrating Botox A may be presented as a 
novel one. BEBs of the patients were controlled by preopera-
tive Botox injection, and the surgeries were performed under 
local anesthesia. Postoperative examinations of the patients 
were performed, procedures like IOP value were measured 
by using applanation tonometer, and the removal of corneal 
sutures were done easily. There are no reports in literature 
concerning the anesthesia options for blepharospasm patients 
who will undergo ocular surgery. Botox A injection prior to 
ocular surgery will increase the patient and the surgeon’s 
comfort alike.
Applying an eye speculum is a must in order to perform 
ocular surgery. However, this may be difficult in cases with 
blepharospasm. After establishment of the eye speculum 
in BEB patients during eye surgery, involuntary closure of 
the eyelid due to blepharospasm will lead to an elevation in 
intraorbital and intraocular pressure. Periodical contractions 
of eyelids and fluctuation of IOP due to this contraction are 
crucial in phacoemulsification because increments of IOP 
could complicate capsulorhexis, and as a result anterior 
chamber depth cannot be preserved. Capsular tear and 
endothelial damage due to reduction in anterior chamber 
depth can be encountered. In glaucoma surgeries and scleral 
fixation secondary intraocular lens implantation, there can be 
rapid decreases in intraocular pressures. In such instances, 
Table 2 Subject details
Disease n f/m  
n/%
Mean age (year) Type of anesthesia
Pterygium 11 7 (63.6)/4 (36.4)   56.3 ± 2.11 Subconjunctival anesthesia
Cataract 10 5 (50)/5 (50) 53.24 ± 1.14 Topical anesthesia
Glaucoma 4 2 (50)/2 (50) 57.87 ± 4.12 Retrobulbar anesthesia
Aphakia 3 2 (66.6)/1 (33.4)   54.7 ± 3.21 Sub-Tenon’s anesthesia
All cases 28 16(57.1)/12(42.9) 55.52 ± 1.53
Note: Values are means ± standard deviation.
Abbreviations: n, number; f, female; m, male.
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involuntary contractions of eyelids may pose as a threat for 
maintenance of anterior chamber depth. It is known that 
glaucoma and previous anterior vitrectomies and hypotonia 
are risk factors for expulsive hemorrhage.22 It is important 
to prevent involuntary eyelid contractions and to avoid 
complications such as expulsive hemorrhage that can result 
from pulsatile intraocular pressure elevation. Endothelial 
damage could occur due to pulsatile contraction of eyelids 
in the patients who underwent intraocular lens implantation 
with scleral fixation. Preoperative application of Botox could 
protect patients having ocular surgery under local anesthesia 
from these potential risks. Preoperative paralyzation of the 
orbitacularis oculi by using local anesthetic drugs in ocular 
surgery of BEB patients was performed easily and safely. 
General anesthesia can be used as an alternative. With the 
aid of these procedures, perioperative akinesis was able to be 
achieved in both groups via safe and comfortable surgery, but 
long-term symptomatic healing and comfort in postoperative 
controls cannot be achieved by procedures other than Botox 
injection in BEB. Moreover, general anesthesia has some 
disadvantages, including premedication necessity, increase 
in the duration of the surgery, possible complications of gen-
eral anesthesia, and increase in hospital admission duration 
postoperatively.
Average onset of the Botox injection’s effect was 
2.8 ± 0.9 (2–5) days in our patients. According to the 
literature, Botox’s effect starts on the third day; the maximum 
effect of Botox sets in 14 days after injection.11,23 Therefore, 
the surgeries were performed 14 days after the injection. 
However, the time of surgery can be determined according 
to the patient’s status after day 3, when the effect of Botox 
starts. Botox’s effect lingered for about 11.5 ± 3.6 weeks. 
This duration is enough for most eyes’ rehabilitation. Ocular 
surgery and postoperative examinations of the patients were 
performed during this period, IOP values were measured, and 
the corneal sutures were removed easily. In studies in which 
long-term follow-ups were conducted of blepharospasm 
patients who had been administered Botox A, it was reported 
that the effect lasts 14 to 16 weeks.11,17,24 The effect of the 
drug fades when the axons elongate and new neuromuscular 
junctions are formed.
In the control of blepharospasm, Botox A can be injected 
in pretarsal and preseptal regions. In our patients, we pre-
ferred the pretarsal injection, due to it being closer to the 
eyelid, more efficient, and having fewer complications. Some 
studies report that the frequency of involuntary blinking 
decreases more and that there are less complications with 
pretarsal administration, which makes it more efficient than 
other techniques.25–27 It has been reported that the average 
initial dose in the control of blepharospasm is between 1.25 
and 5 U.28 We used 2.5 U, and this dose was enough for all 
patients.
After Botox injection, complications such as eyelid 
ecchymosis, ptosis, diplopia, and watery eyes after injection 
in medial cantus region were reported. Following injection, 
there was eyelid echimosis in two patients (7%) and ptosis 
in one patient (3.6%). In some studies, it was reported that 
postinjection ptosis rates varied between 10.3% and 9.2%, 
and chemosis rates were between 7% and 8.2%.11,29 Our 
ptosis rates were much lower than the previous   studies, 
suggesting these values were due to our preference of 
  pretarsal injection.
Conclusion
Pretarsal Botox A injection in BEB patients prior to ocular 
surgery is an efficient and safe procedure that helps the 
surgery to be performed under local or topical anesthesia. 
Additionally, by using this procedure, postoperative 
examination and postoperative intervention on the eye can 
be performed easily.
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